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Current challenges
he most critical difficulty with the concept of
MCI is that it is an arbitrary label on a continuum of
cognitive changes that occur in people as they age.
1As a
result, there is considerable practice variation, even
among experts who apply the label.
2-4 The arbitrary
nature of the label can be seen most explicitly in the
neuropsychological criteria, which may specify the
threshold for applying the terms (one or one and a half
standard deviations less than age-matched controls),the
composition of the battery,and the norms.
5,6The criteria
concerning preserved or relatively preserved activities
of daily living also permit considerable variability as to
where the line is drawn by different clinicians.How com-
plex must an impaired instrumental activity of daily liv-
ing be before the label MCI is applied? For that matter,
how simple should the task be before the affected per-
son is said to convert to Alzheimer’s disease (AD)?
7,8
Differences in an individual’s performance of life’s tasks
create both patient and clinician variability in percep-
tions as well as cross-cultural challenges in multinational
studies (Gaines A,Whitehouse PJ,unpublished data).
The existence of a continuum of cognitive changes is
illustrated by MCI being bounded on one side by AD
and on the other by labels such as age-associated mem-
ory impairment (AAMI)
9 or age-related cognitive
decline.
10 The emergence of AAMI was also closely
linked to attempts to develop medicines to treat this
condition.The criteria for applying this label included
demonstrating test performance one standard deviation
below younger-age controls, thus creating a large num-
ber of older individuals who could be labeled with
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The development of the concept of mild cognitive impair-
ment (MCI) and its practical application have been inti-
mately tied to attempts to produce therapeutic agents.
Understanding the regulatory environment and deter-
mining the way in which it can be influenced are critical
to the development of drugs and their eventual approval.
In this article, we review some of the current challenges
surrounding the concept of MCI relevant to drug devel-
opment, summarize activities in various regions of the
world, and conclude with some suggested next steps and
an alternative framing for approving drugs for MCI and
related conditions.  
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heart of the conceptual and practical ambiguities asso-
ciated with this concept.
Clinicians know logically that there is a time in the life
course of a patient,who will eventually be diagnosed as
having AD,when the symptoms are present,but not suf-
ficiently severe to warrant the label dementia.Any pro-
gressive medical condition must have a phase in which
the symptoms are emerging, but not of sufficient inten-
sity to warrant a disease label. In medicine, increasing
attention is being paid to so-called preclinical states,such
as in hypertension,depression,and Parkinson’s disease.
Thus, it is not at all surprising that different variants of
MCI have been identified,including amnestic MCI,MCI
with symptoms in several different cognitive domains,
and MCI with focal symptoms in an intellectual area
other than memory.
8,11 The MCI associated with frontal
lobe dementia and vascular dementia would more likely
be predicted to be nonamnestic.
The symptoms in MCI are mild and perhaps more vari-
able than in dementia;therefore,it is not surprising that
the outcomes of longitudinal follow-up studies and drug
studies might also be more variable.The logically com-
plete set of outcomes for a patient with MCI includes no
change over time,further deterioration or even improve-
ment.All these outcomes can be demonstrated in epi-
demiological studies when patients are followed for sev-
eral years.
5 Most experts suggest that the conversion rate
to dementia is approximately 15% a year.
6 There are,
however,some people who improve,at least for a period
of time, suggesting either a benign course to their med-
ical condition or a mislabeling of the individual in the
first place, perhaps due to a bad testing day or mild
depression. If one accepts the 15% annual conversion
rate, one also has to ask what happens over a more
extended period of time,such as that usually associated
with epidemiological studies.At 15% a year, most peo-
ple would have been expected to convert to AD within
10 years.This point returns us to the issue of MCI as an
arbitrary label on the continuum of cognitive aging and
raises the unresolved question of whether all human
beings would develop AD if they lived long enough.
Most studies of those in their 80s, 90s, and beyond sug-
gest that the incidence of AD continues to increase with
age.
12
Thus, the major conceptual challenge to the further
development of drugs to treat MCI is the ambiguity
around definition and the relationship to normal aging.
Other challenges also exist in the development of trial
designs to demonstrate the effectiveness and safety of
drugs. One clear issue is what the therapeutic goal is.
Most studies are classified as either trials to demonstrate
symptomatic benefit or trials to demonstrate disease
modification. Most of the interest in MCI surfaced
because of the desire to develop medications to prevent
AD.In order to conduct a primary prevention protocol,
one needs to enter into the study individuals who do not
currently suffer from dementia.One of the easiest ways
to enrich the sample in a prevention study is to include
people who already suffer from minor degrees of cogni-
tive difficulties,as they are more likely to proceed to full
dementia.Of course,this begs the question as to whether
this is primary prevention, or really secondary preven-
tion in which the enrolled individuals were already suf-
fering from a dementia at an early stage and the
observed deterioration was the further progression of
the already existing disease condition.
The problem with conducting either primary or sec-
ondary prevention studies is that there are no agreed-
upon designs.
13 Survival analysis as promoted by the
National Institute of Aging’s Alzheimer’s Disease
Cooperative Study in their studies of vitamin E, for
example,cannot clearly differentiate a prolonged symp-
tomatic benefit from a disease-modifying or neuropro-
tective effect.
14,15 The staggered-start, staggered-stop
design,elaborated most clearly by Leber,has been used
in a few studies.
16 However,it has been difficult for reg-
ulators to interpret the complex slope changes necessary
to make the claim that a drug is disease-modifying.
Although considerable effort has been placed in devel-
oping biological markers,particularly neuroimaging,no
test can currently replace a clinical diagnostic process for
MCI.
14 Regulatory bodies will most likely not consider
surrogate markers such as hippocampal atrophy unless
they are clearly linked to clinical improvement.Thus,
from a regulatory perspective, we are puzzled to know
what designs to use to demonstrate a disease-modifying
process that prevents the conversion of MCI to AD.
Attempts have also been made to demonstrate that
medications provide symptomatic benefit for people
with MCI.Such studies have been designed in a fashion
parallel to those in AD,using outcome measures tailored
to persons with less cognitive impairment.Here,the con-
ceptual challenges are less evident in developing the trial
designs,but the practical implications of such studies are
perhaps less clear. Even if such studies show positive
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and the pharmacoeconomic impacts on societies?
17
Another area of conceptual and practical confusion that
permeates the study of people with mild degrees of cog-
nitive impairment is the overlap with the emerging field
of cognitive enhancement.
18At what point on the contin-
uum of cognitive aging is a drug not treating a disease,but
rather enhancing a person’s normal ability to function
intellectually.Our pilot study of the use of donepezil in
53-year-old pilots flying in flight simulators suggests that
cholinergic drugs may benefit individuals in their middle
years who are performing complex cognitive tasks in soci-
ety.
19 Studies of the biology of brain aging, particularly
changes in neurotransmitter systems,support the idea that
persons with AD and MCI lie on the continuum of neu-
ronal alterations that begin perhaps quite early in life.
20
A related conceptual and practical problem in develop-
ing drugs to treat MCI is the overlap between Western
scientific allopathic medicine and so-called complemen-
tary and alternative medicine (Whitehouse PJ,Juengst E,
unpublished data). Many individuals take herbal and
nutraceutical products to try to improve their memories
or slow the progression of age-related cognitive deterio-
ration.Such therapies to treat brain aging overlap with
those designed to slow the aging process itself.Practically,
this means that decisions must be made about whether
to enroll individuals in studies who are taking such prod-
ucts (and at what doses).Conceptually,and from a regu-
latory perspective,it raises issues of what products are to
be regulated by the Food and Drug Administration
(FDA) and other drug regulatory bodies or monitored
through other means or by no means at all.In both the
USA and Europe,there is increasing concern about the
lack of oversight of such complementary and alternative
medicines.
21Yet,as we have seen,it is not often easy to
place agents in one category or another.Vitamin E and
ginkgo are examples of biological products that have
been sold as essentially unregulated products,but that
are also being studied scientifically.
A final major area of challenge to the development of
more effective drugs from MCI is ethics.
22 MCI was
developed as a concept to help develop medications to
prevent AD.This is a laudable but very ambitious—and
perhaps even overly ambiguous—goal. Given current
science and resources, what would a drug profile look
like that cured or prevented AD? How would this affect
people with MCI and even completely normal individu-
als? How safe would such a product need to be?
The label MCI was developed in a research context.
What are the implications of such a term for the individ-
ual labeled with it and for their partner and potential
caregiver (Corner L, Bond J, unpublished data)?
23 The
variable use of the concept of MCI creates considerable
confusion.If I have a label of MCI,does that mean that
I do not have AD, that I have a mild form of AD or
another dementia, or that I may or will eventually get
dementia? Moreover,we already noted that some per-
sons with the label MCI improve.The implications of the
term MCI for an individual patient and clinician are
closely linked to the fear of AD itself. Perhaps in our
enthusiasm for creating new medications,we have also
intensified the terror that people feel about the possibil-
ity of suffering from dementia.
24
Perhaps the greatest ethical issue facing the develop-
ment of drugs for cognitive impairment has to do with
conflict of interest between researchers,physicians,and
the drug industry.
25The acceptance of MCI as the thera-
peutic target would expand the markets enormously.
One of the lessons of the introduction of drugs to treat
erectile dysfunction is that the line between disease and
normality is thin. Moreover, the ability to enhance cog-
nition already motivates many people to take comple-
mentary and alternative medical products.The interest
in the market is therefore profit—a strong motivator.
Recent publicity has focused on the relationship
between physicians and industry.The concern about the
use of serotonin reuptake blockers to treat depression
in childhood is but one example.
26A major challenge to
biological psychiatry,but also to neurology,is maintain-
ing the trust of our research participants and patients.
One important issue that surfaced around the treatment
of depression is the suppression of negative trials.We
need to ensure that trials in dementia are entered into
an international database and that the trial results made
available to the scientific community or that research
subjects are appropriately compensated.
27
Fees paid to experts are a necessary part of doing busi-
ness.What is appropriate commensuration? Academic
experts for hire as authors of papers in which their con-
tributions are limited is another example of a major
problem.The pharmaceutical industry is amazingly effec-
tive at not only selling their drugs,but also at influencing
the very way we think about health. The amount of
money put into drug treatments limits our incentive to
think about alternative ways of addressing social prob-
lems due to various age-related cognitive challenges.
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United States of America
The FDA held a one-day hearing in March 2001 to
address some of the conceptual issues surrounding the
development of drugs for MCI. Although no official
statement was made concerning the acceptability of
MCI as a therapeutic target, many experts interpreted
the FDA’s position that MCI is very early dementia,
most likely AD. Further elaboration of this issue will
likely require submission by industry of drugs for MCI
to the FDA for consideration for approval.The regula-
tory process in the USA is relatively open.Whether or
not experts believe that a diagnostic entity is an appro-
priate target for drug development influences the reg-
ulators in the evaluation of protocols.
Europe
The European Medicines Evaluation Agency (EMEA)
has not held open hearings about the concept of MCI.
Individual members of their committees have spoken at
scientific meetings. Such presentations suggest that the
attitude in Europe is similar to that in the USA, ie, the
regulators will wait for more development in the field
and for the submission of actual trials.
Canada
In the fall of 2004, a group of investigators in Canada
will meet to examine the draft academic guidelines that
were issued several years ago. Regulators will be
involved in the meeting, and the topic of MCI and
related conditions will be discussed. It is uncertain
whether these guidelines will be considered official gov-
ernment position.
Asia
No regulatory bodies in Asia have taken a stance on
MCI as a target condition. Under the auspices of the
International Working Group for the Harmonization of
Dementia Drug Guidelines,organized for the first time
8 years ago by the author and currently by Jean-Marc
Orgogozo, three Asian regional meetings have been
held. From the first in Singapore in 2001, to the second
in China, and now this year in Thailand, there has been
growing interest in the concept of MCI among academic
opinion leaders in Asia.
28,29 Of course,this is largely influ-
enced by the Western experts expressing their enthusi-
asm for the concept.
Attitudes toward the elderly and to age-related cognitive
changes are different in Asia.The back-translation into
English of the term,MCI,by a leading opinion leader in
China is “loss of wisdom”(Prof Xu,personal communica-
tion).Labeling millions of Chinese with this term has some
interesting social implications and potentially profound
effects on attitudes toward the elderly in China.
International issues
A variety of international professional organizations
have organized meetings about MCI.The International
Working Group for the Harmonization of Dementia
Drug Guidelines has had regulatory issues at the heart
of its mission to promote global discussion about designs
to treat MCI, AD, and other conditions like vascular
dementia. Currently under the direction of Lon
Schneider with input from other experts, including the
author, a manuscript addressing regulatory aspects of
drug development for MCI is being prepared. The
International Psychogeriatric Association is also plan-
ning a meeting for this winter (2004) on MCI,which will
involve discussions about regulatory issues.
Future directions
This author believes that a fundamental rethinking of
MCI is necessary. He doubts that more conferences
alone will lead to consensus,since there have been many
such conferences and the differences of opinion remain.
At the 9th Conference on Alzheimer’s Disease and
Related Disorders in Philadelphia,Pa,in July 2004,this
author received the impression of a growing split
between the USA and Europe.In fact,within the USA,
the original Mayo Clinic concept of the MCI (perhaps
to be renamed Petersen’s syndrome) is still meeting
resistance.
The main issue that remains is the need to address more
seriously the continuum of aging. Of course, such a
reconsideration of the categories of age-related cogni-
tive impairment would have implications for AD as
well.
30 Despite the work in genetics and neuroimaging,
we are having a harder time differentiating the various
types of dementia from each other.
11 This is most likely
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affects individuals in many different ways and our
attempts to assign dementias into discrete categories are
failing because of the overlap in biologies at work in our
brain.
31Vascular and neurodegenerative processes inter-
act.Neuronal loss occurs in multiple different systems to
different degrees creating a wide spectrum of cognitive,
affective,and motor symptoms.
Is there a regulatory implication for the development of
medications to treat cognitive impairment? As I have sug-
gested previously,
1 it may be possible to treat cognitive
impairment as a nonspecific symptom rather than a fea-
ture of different discrete conditions.The biological sub-
strate for such a claim is that overall loss occurs continu-
ously in various brain nuclei as we age.For example,loss
of cells in the cholinergic basal forebrain occurs in a vari-
ety of dementias and with normal aging.Cholinesterase
inhibitors appear to work,albeit in modest ways,in a vari-
ety of dementias characterized by cholinergic pathology,
including not only AD,but also Parkinson’s disease,vas-
cular dementia,and other overlapping conditions.
Could we consider cognitive impairment like pain?
Perhaps an analogy closer to home is the treatment of
agitation in dementia. Psychosis, which may be consid-
ered a discrete category,exists in a variety of conditions;
agitation occurs on a continuum.Drugs to treat agitation
are being developed and submitted for approval based
on finding positive effects in three or more conditions,
like dementia and mental retardation. Could we con-
sider submitting a portfolio of results for a drug to treat
cognitive impairment in several conditions and get a
label for a general indication? Such an approach would
not only avoid the problems of nosology in the field of
dementia,which are only increasing,but allow the use of
these medications to treat mild degrees of symptoms as
well as more profound cognitive deficits.
Such an approach would greatly expand the market for
potential therapies.It might even allow normal individ-
uals to take medications for cognitive enhancement.The
boundaries between what is a disease and what is nor-
mality would grow even more unclear with an approach
that labels cognitive impairment on a continuum.
Physicians might be tempted to prescribe the medica-
tions for a larger number of individuals. The costs of
drugs to our health care system would likely increase.As
an advocate for the importance of pharmacoeconomic
studies,especially studies of quality of life,I would urge
that we stress the importance of such cost–utility
approaches even in the current regulatory and reim-
bursement environment,and even if that would increase
the size of the potential market.
A focus on drug treatment for cognitive impairment lim-
its our thinking in several ways. First, we are constantly
focusing on what is wrong with our cognition as we age.
More emphasis on cognitive vitality and the potential for
older people to further develop cognitively and gain wis-
dom would be helpful in society. Moreover, a focus on
drugs makes us think that the only answers to the chal-
lenges of cognitive aging lie in medicine and biology.
Clearly, there are many ways to prevent the deteriora-
tion that can occur in cognitive abilities as we age,
besides waiting for a magic bullet.Developing a sense of
purpose, engaging in civic activities, and taking respon-
sibility for one’s personal legacy are all activities that can
contribute to a sense of cognitive vitality,even in persons
who suffer from MCI and AD.
32 ❏
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Aspectos regulatorios del deterioro 
cognitivo leve: hacia una perspectiva 
armonizadora
El desarrollo del concepto de deterioro cognitivo
leve (DCL) y su aplicación práctica han estado ínti-
mamente vinculados con intentos por producir
agentes terapéuticos. La comprensión del marco
regulatorio y la determinación de la vía mediante
la cual puede ser influenciado son críticos para el
desarrollo de fármacos y su eventual aprobación.
En este artículo se revisan algunos de los desafíos
actuales alrededor del concepto de DCL que son
relevantes para el desarrollo de fármacos, se resu-
men actividades en varias regiones del mundo y se
concluye con algunas sugerencias de próximos
pasos y una estructura alternativa para la aproba-
ción de fármacos para el DCL y condiciones relacio-
nadas. 
Aspects réglementaires du déficit cognitif
léger : vers un avenir harmonisé
Le développement du concept de déficit cognitif
léger (Mild Cognitive Impairment, MCI) et ses appli-
cations pratiques ont été intimement liés aux ten-
tatives d’obtenir des agents thérapeutiques. La
compréhension de l’environnement réglementaire
et de la manière dont il peut être influencé est cru-
ciale pour le développement des médicaments et
leur agrément éventuel. Dans cet article, nous pas-
sons en revue certains défis actuels autour du con-
cept de MCI et du développement de médicaments
s’y rapportant, nous résumons les positions régle-
mentaires adoptées dans diverses régions du
monde et nous proposons en conclusion des orien-
tations possibles dans l’avenir ainsi qu’un autre
encadrement pour l’agrément des médicaments du
MCI et des maladies qui y sont liées.